Profile-QSAR and Surrogate AutoShim Protein-Family Modeling of Proteases

The 2D Profile-QSAR and 3D Surrogate AutoShim protein-family virtual screening methods were originally developed for kinases. They are the key components of an iterative medium-throughput screening alternative to expensive and time-consuming experimental high-throughput screening. Encouraged by the success with kinases, the S1-serine proteases were selected as a second protein family to tackle, based on the structural and SAR similarity among them, availability of structural and bioactivity data, and the current and future small-molecule drug discovery interest. A validation study on 24 S1-serine protease assay data sets from 16 unique proteases gave very promising results. Profile-QSAR gave a median R(ext)² = 0.60 for 24 assay data sets, and pairwise selectivity modeling on 60 protease pairs gave a median R(ext)² = 0.64, comparable to the performance for kinases. A 17-structure universal ensemble S1-serine protease surrogate receptor for Autoshim was developed from a collection of ~1500 X-ray structures. The predictive performance on 24 S1-serine protease assays was good, with a median R(ext)² = 0.41, but lower than had been obtained for kinases. Analysis suggested that the higher structural diversity of the protease structures, as well as smaller assay data sets and fewer potent compounds, both contributed to the decreased predictive power. In a prospective virtual screening application, 32 compounds were ordered from a 1.5 million archive and tested in a biochemical assay. Thirteen of the 32 compounds were active at IC₅₀ ≤ 10 μM, a 41% hit-rate. Three new scaffolds were identified which are being followed up with testing of additional analogues. A SAR similarity analysis for this target against 13 other proteases also indicated two potential protease targets which were positively and negatively correlated with the activity of the target protease.

[1]  D. Fairlie,et al.  Protease inhibitors in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[2]  J. Powers,et al.  Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases , 2003 .

[3]  L. Hedstrom Serine protease mechanism and specificity. , 2002, Chemical reviews.

[4]  Eric J. Martin,et al.  Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..

[5]  H. Katus,et al.  New antithrombotic drugs on the horizon , 2003, Expert opinion on investigational drugs.

[6]  B. Turk Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.

[7]  N. Rawlings,et al.  Evolutionary families of peptidases. , 1993, The Biochemical journal.

[8]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[9]  Eric J. Martin,et al.  Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure , 2008, J. Chem. Inf. Model..

[10]  Ingemar Nilsson,et al.  A new oral anticoagulant: the 50-year challenge , 2004, Nature Reviews Drug Discovery.

[11]  James F. Riordan,et al.  Ace revisited: A new target for structure-based drug design , 2003, Nature Reviews Drug Discovery.

[12]  Erik De Clercq,et al.  Antiviral drugs in current clinical use. , 2004 .

[13]  G. Salvesen,et al.  Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.

[14]  D. C. Sullivan,et al.  AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data. , 2008 .

[15]  Jeffrey Jie-Lou Liao,et al.  Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .

[16]  Eric J. Martin,et al.  AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data , 2008, J. Chem. Inf. Model..

[17]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[18]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[19]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[20]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[21]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[22]  Jun Kong,et al.  MEROPS: the peptidase database. , 2004, Nucleic acids research.

[23]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.